The US FTC issues a report on authorized generic drugs expressing concern that they are being used to delay generic competition
U.S. FTC Scrutinizes Interplay Between Authorized Generics and Patent Settlements*
The U.S. Federal Trade Commission has recently released two reports relating to the pharmaceutical industry. A significant theme in both reports is a concern that brand name pharmaceutical companies are (...)